04:32 PM EDT, 08/23/2024 (MT Newswires) -- Scisparc ( SPRC ) said late Friday it has filed an investigational new drug application with the US Food and Drug Administration for a phase 2b trial of SCI-110 to treat Tourette Syndrome, a condition of the nervous system.

The trial will be conducted at the Yale Child Study Center at the Yale School of Medicine in Connecticut, the Hannover Medical School in Hannover, Germany, and at the Tel Aviv Sourasky Medical Center in Israel, the clinical-stage drugmaker said.

The shares jumped past 38% in after-hours trading.

Price: 0.5048, Change: +0.14, Percent Change: +37.55